Author:
Voloshyna Natalia,Vasylovskyi Vitalii,Chernenko Maksym
Publisher
Public Organization Association of Neurologists, Psychiatrists and Narcologists of Ukraine
Reference47 articles.
1. Muratova T. M., Nehrych T. I., Voloshyna N. P. ta in. Rozsiianyi skleroz v Ukraini: personalizovana stratehiia likuvannia. Zdorovia Ukrainy. 2020. No. 2. S. 14—16. URL: https://health-ua. com/multimedia/5/0/2/7/4/1593093235.pdf.
2. E. G. Celius, H. Thompson, M. Pontaga [et. al.] Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives. Patient Prefer Adherence. 2021. Vol. 15. P. 15—27. DOI: 10.2147/PPA.S268829.
3. X. Montalban, R. Gold, A. J. Thompson et al. ECTRIMS/ EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult. Scler. 2018. No. 24(2). Р. 96—120. DOI: 10.1177/1352458517751049.
4. H. P. Hartung, R. Gonsette, N. Konig et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, doubleblind, randomised, multicentre trial. Lancet. 2002. No. 360 (9350). Р. 2018—2025. DOI: 10.1016/S0140-6736(02)12023-X.
5. X. Montalban, S. L. Hauser, L. Kappos et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017. No. 376 (3). Р. 209—210. DOI: 10.1056/ NEJMoa1606468.